<DOC>
	<DOCNO>NCT02677493</DOCNO>
	<brief_summary>This study evaluate immunogenicity safety 'IL-YANG Quadrivalent Influenza Vaccine Inj . ' healthy male female adult age 19 older .</brief_summary>
	<brief_title>Study Evaluate Immunogenicity Safety 'IL-YANG Quadrivalent Influenza Vaccine Inj . '</brief_title>
	<detailed_description>In study , eligible subject study base inclusion/exclusion criterion randomize follow stratification group age receive one dose test vaccine , comparator 1 , comparator 2 . - Group A : healthy adult age ≥ 19 &lt; 65 . - Group B : healthy adult age ≥ 65 . During study participation , investigator ass immunogenicity safety subject . The investigator perform immunogenicity test Visits 1 3 ( end study visit ) immunogenicity evaluation ( prior investigational product vaccination ) instruct subject record AEs occur investigational product vaccination safety assessment . A blood sample collect subject assign subject number . Following intramuscular injection 0.5mL investigational product deltoid muscle shoulder , subject study visit Week 4 blood sample antibody titer test . In addition , telephone visit perform assess serious AEs ( SAEs ) Day 180 vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy men woman age 19 older . Women childbearing potential must negative pregnancy test ( urine HCG ) screen visit . Subjects give , fully understood , information study , provide voluntary write informed consent participate study comply applicable study requirement . Subjects know allergy egg , chicken , component study vaccine . Subjects received influenza vaccine within last 6 month prior study entry . Subjects immune function disorder include immunodeficiency disease relevant family history . Subjects donate blood within 1 week prior vaccination plan donate blood period Day 1 Month 7 vaccination . Subjects history GuillainBarre syndrome . Subjects Down 's syndrome cytogenetic disorder . Subjects consider investigator difficulty study participation due severe chronic disease ( e.g. , cardiovascular disease except control hypertension respiratory diseases respiratory failure , metabolic disease , renal function disorder , hemoglobinopathy , etc. ) . Subjects hemophilia coagulation disorder , increase risk serious bleed intramuscular injection . Subjects acute fever body temperature &gt; 38.0 ºC within 72 hour prior administration study vaccine . Subjects receive another vaccine within 28 day administration study vaccine plan receive another vaccine study . Subjects receive immunosuppressant immune modify drug within 3 month prior investigational product vaccination . 1 . Azathioprine , cyclosporin , interferon , GCSF , tacrolimus , everolimus , sirolimus , etc . 2 . High dose corticosteroid ( subject take high dos , define 2mg/kg/day high prednisolone administer long 14 consecutive day , eligible study . The use inhale , nasal topical corticosteroid allow , regardless dos ) . Subjects previously receive immunoglobulin bloodderived product within last 3 month prior administration study vaccine , schedule receive treatment bloodderived product study . Subjects participate another clinical trial within 30 day administration study vaccine . Female subject childbearing potential agree use acceptable method birth control* study study period . Medically acceptable method birth control : condom , injectable implantable contraceptive , intrauterine device , oral contraceptive , etc . Subjects clinically significant medical psychiatric illness investigator 's opinion , suitable study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>